← Eichor
Study identifier: NCT07390240 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia

Condition: Hypophosphatasia  ·  Sponsor: AstraZeneca

PhaseN/A
Planned participants55
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The effect of monoallelic variants in the ALPL gene on the natural course of hypophosphatasia (HPP) in children and adults in Russia (ATLANTIS)

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center  ·  1-877-240-9479  ·  information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (4)

Research siteMoscow, RussiaCompleted
Research SiteMoscow, RussiaRecruiting
Research SiteRostov-on-Don, RussiaRecruiting
Research siteSaint Petersburg, RussiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07390240